Intellia Therapeutics Inc

18 wrz 2026, 23:11 UTC

Intellia Therapeutics Inc is experiencing a modest decline in after-market hours, trading near the lower end of its one-month range.

17 wrz 2026, 20:02 UTC

Intellia Therapeutics is advancing sharply, reflecting positive trends in biotechnology, while the ARK Genomic Revolution ETF gains from strong performances by Tempus AI and others.

16 wrz 2026, 23:11 UTC

Intellia Therapeutics Inc is trading higher in after-market hours, supported by stronger-than-expected U.S. retail sales data indicating robust consumer spending.

15 wrz 2026, 23:02 UTC

Intellia Therapeutics Inc shares are higher in after-market hours amid ongoing discussions about its Biologics License Application and market sentiment.

14 wrz 2026, 20:07 UTC

Intellia Therapeutics shares are higher, rebounding from earlier session lows amid a broader market recovery, though still below the 20-day moving average.

10 wrz 2026, 19:16 UTC

Intellia Therapeutics Inc shares are lower today, following a notable decline from Wednesday's close amid broader market sentiment after the ECB raised interest rates.

8 wrz 2026, 20:07 UTC

Intellia Therapeutics' shares decline despite FDA accepting its lonvo-z application for Priority Review, targeting a decision by March 2027.

3 wrz 2026, 19:16 UTC

Intellia Therapeutics shares are lower, reflecting sector pressure and a notable decline in first-quarter results. Correlated asset CRISPR Therapeutics also experienced a downturn.

1 wrz 2026, 20:09 UTC

Intellia Therapeutics is lower today, tracking broader market declines amid rising oil prices and increased U.S. Treasury yields, which raise inflation concerns.

31 sie 2026, 23:21 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from recent declines and positioned above their 20-day moving average.

28 sie 2026, 20:08 UTC

Intellia Therapeutics shares are lower today, continuing a recent downward trend amid rising U.S. Treasury yields and broader market weakness. No specific news was identified.

27 sie 2026, 23:41 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, recovering from an earlier dip and surpassing their 20-day moving average. No specific news was identified.

26 sie 2026, 23:11 UTC

Intellia Therapeutics Inc is higher in after-market hours, reflecting broader market gains. The asset remains above its 20-day moving average and near its one-month range.

25 sie 2026, 20:09 UTC

Citizens reiterated its Market Outperform rating on Intellia Therapeutics and maintained a $30 price target, contributing to positive sentiment and higher shares.

24 sie 2026, 23:01 UTC

Intellia Therapeutics shares declined after-market, moving lower from Monday's close. The stock remains above its 20-day moving average and near its one-month range.

21 sie 2026, 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

20 sie 2026, 19:26 UTC

Intellia Therapeutics shares are lower, reflecting declines in the biotechnology sector and the Russell 2000 Index amid challenging market conditions.

19 sie 2026, 20:02 UTC

Intellia Therapeutics shares are higher today, reflecting strong investor interest and positive sentiment in the genomics sector, aided by gains in ARK and CRSP.

17 sie 2026, 19:36 UTC

Intellia Therapeutics Inc shares are higher, continuing an upward trend since Friday amid positive sentiment in the biotechnology sector and rising long-term Treasury yields.

14 sie 2026, 23:31 UTC

Intellia Therapeutics Inc. shares rose in after-market trading, reflecting positive market dynamics. The stock remains above its 20-day moving average.

11 sie 2026, 19:33 UTC

Intellia Therapeutics shares are lower after Brookline Capital Markets revised Q2 2026 earnings estimates to a loss of -$0.80 per share.

10 sie 2026, 19:46 UTC

Intellia Therapeutics shares rise as analysts boost price targets, with Wedbush raising its target to $17.00 while maintaining a “neutral” rating.

7 sie 2026, 19:26 UTC

Evercore ISI upgraded Intellia Therapeutics to Outperform and raised its price target to $24, contributing to gains in the stock during Friday's session.

6 sie 2026, 23:06 UTC

Intellia Therapeutics Inc shares are higher in after-market hours, reflecting increased trading activity despite being near the lower end of its one-month range.

4 sie 2026, 19:36 UTC

Shares higher today, reflecting gains in SPDR S&P Biotech ETF.

3 sie 2026, 19:36 UTC

Intellia Therapeutics Inc. shares are trading higher amid broader small-cap market strength, recovering from an earlier dip during Monday's session.

31 lip 2026, 20:06 UTC

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

30 lip 2026, 17:57 UTC

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

29 lip 2026, 23:31 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

28 lip 2026, 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.